6Bernardeschi P, Giustarini G, Mon - tenora I, et al. Thalidomid plusmonthly high- dose dexamethasone in chemorefrac- tory myeloma. Results of a phase II clinical study[J]. In Vivo,2006,20(6A) :719 - 720. 被引量：1
2Singhal S,Mehta J,Desikan R,et al.Antitumor activity of thalidomide in refractory multiple myeloma[J].N Engl J Med,1999,341(21):1565. 被引量：1
3Barlogie B,Desikan R,Eddlemon P,et al.Extended survival in advanced and refractory multiple myeloma after single agent thalidomide:identification of prognostic factors in a phase 2 study of 169 patients[J].Blood,2001,98(2):492-494. 被引量：1
4Kyle R A,Rajkumar S V.Therapeutie application of thalidomide in multiple myeloma[J].Semin-Oncol,2001,28(6):588-592. 被引量：1
5Hideshima T,Chauhan D,Shima Y,et al.Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy[J].Blood,2000,96(9):2943-2950. 被引量：1
7Singhal S,Mehta J,Desikan R,et al.Antitumor activity of thalidomide in refractorymultiple myeloma[J].N Engl J Med,1999,341(18):1565 -1571. 被引量：1
8Marriott JB,Muller G,Dalgleish AG.Thalidomide as an emerging immunotherapeuticagent[J].Immunol Today,1999,20(7):538 - 540. 被引量：1
9Davies FE,Raje N,Hideshima T,et al.Thalidomide and immunomodu latory derivatives augment natural killer cell cytotoxicity in multiple myeloma[J].Blood,2001,98(1):210 - 216. 被引量：1
10Tosi P,Zamagni E,Cellini C,et al.Thalidomide alone or in combination with dexamethasone in patients with advanced,relapsed or refractory multiple myeloma and renal failure[J].Eur J Haematol,2004,73(2):98. 被引量：1
4Singhal S ,Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [J].N Engl J Med,1999,341(21):1565. 被引量：1
5Casado J G, Pawelec G, Morgado S, et al. Expression of adhe sion molecules and ligands for activating and costimulatory re- ceptors involved in cell mediated cytotoxieity in a large panel of human melanoma cell lines[J]. Cancer Immunol Immunother, 2009,58(9) :1517-1526. 被引量：1
6Stern-Ginossar N, Mandelboim O. An integrated view of the regula- tion of NKG2D ligands[J]. Immunology, 2009,128 (1) : 1-6. 被引量：1
7Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses[J]. Immunol Rev, 2010,235 (1) : 267-285. 被引量：1
8Das G, La Rocca R, Lakshmikanth T, et al. Monitoring human leukocyte antigen class I molecules by micro Raman spectroscopy at single-cell level[J]. J Biomed Opt,2010,15(2):027007. 被引量：1
9Gasser S, Raulet DH. Activation and self-tolerance of natural killer cells [J]. Immunol, 2006, 214(1) :130-142. 被引量：1
10Li P, Morris DL, Willcox BE, et al. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like lig- and MICA[J]. Nat Immunol, 2001, 2(5):443-451. 被引量：1
